MedTrace Logo

Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

NCT01234558 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2012-09-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.

Conditions

Interventions

DRUG

GLYX-13

single IV dose

Sponsors & Collaborators

  • Naurex, Inc, an affiliate of Allergan plc

    lead INDUSTRY

Principal Investigators

  • Ronald M Burch, MD, PhD · Naurex, Inc, an affiliate of Allergan plc

  • Vishaal Mehra, MD · Artemis Clinical Research, San Diego CA

  • Raymond Manning, MD · CNRI-LA, Pico Rivera CA

  • Paul Gross, MD · Lehigh Center for Clinical Research, Allentown PA

  • Surinder Randhawa, MD · Lynn Health Sciences Institute, Oklahoma City OK

  • David Greuner, MD · CRI-WW, Philadelphia PA

  • David Krefetz, DO · CRI-WW Lordes Hospital, Willingboro NJ

  • Benji Kurian, MD · U Texas SW Medical Center, Dallas TX

  • Michael Lesem, MD · Claghorn-Lesem Research Clinic, Houston TX

  • Matthew Macaluso, MD · Clinical Research Center, Univ Kansas, Wichita KS

  • Stephen Murray, MD PhD · Clinilabs, New York, NY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-06-30
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01234558 on ClinicalTrials.gov